Form 4: Leap Therapeutics Director William Li Acquires Stock Options
SEC Form 4 Filing
Director William Li acquired 25,000 stock options in Leap Therapeutics, Inc. on October 2, 2024, according to a recent SEC filing.
Summary
- On October 2, 2024, William Li, a director of Leap Therapeutics, Inc. (LPTX), was granted 25,000 stock options.
- The options have an exercise price of $2.45.
- The options vest in four quarterly installments starting December 31, 2024, and ending September 30, 2025, contingent upon continued service as a director, consultant, or service provider.
- The options expire on October 2, 2034.
Sentiment
Score: 5
Explanation: The document simply reports a stock option grant, which is a neutral event. It doesn't inherently indicate positive or negative sentiment.
Future Outlook
The options vest over time, incentivizing continued service from the director.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 10/02/2024 | Date of transaction: William Li acquired 25,000 stock options. |
| 10/02/2024 | Stock option grant date. |
| 12/31/2024 | First quarterly vesting date for the stock options. |
| 03/31/2025 | Second quarterly vesting date for the stock options. |
| 06/30/2025 | Third quarterly vesting date for the stock options. |
| 09/30/2025 | Fourth quarterly vesting date for the stock options. |
| 10/02/2034 | Expiration date of the stock options. |
| 10/04/2024 | Date of signature on the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.